PREVACID Drug Patent Profile

Which patents cover Prevacid, and when can generic versions of Prevacid launch?

Prevacid is a drug marketed by Takeda Pharms Usa, Takeda Pharms Na, and Perrigo Pharma Intl. and is included in six NDAs.

The generic ingredient in PREVACID is lansoprazole; naproxen. There are fifty-six drug master file entries for this compound. Additional details are available on the lansoprazole; naproxen profile page.

Summary for PREVACID

US Patents:	0
Applicants:	3
NDAs:	6
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for PREVACID

Paragraph IV (Patent) Challenges for PREVACID

Tradename	Dosage	Ingredient	Strength	NDA	ANDAs Submitted	Submissiondate
PREVACID	Delayed-release Orally Disintegrating Tablets	lansoprazole	15 mg and 30 mg	021428	1	2006-12-27
PREVACID	Delayed-release Pellets/Capsules	lansoprazole	15 mg and 30 mg	020406		2005-12-05

US Patents and Regulatory Information for PREVACID

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Takeda Pharms Usa	PREVACID	lansoprazole	CAPSULE, DELAYED REL PELLETS;ORAL	020406-001	May 10, 1995		DISCN	Yes	No
Perrigo Pharma Intl	PREVACID 24 HR	lansoprazole	CAPSULE, DELAYED REL PELLETS;ORAL	022327-001	May 18, 2009		OTC	Yes	Yes
Takeda Pharms Na	PREVACID	lansoprazole	FOR SUSPENSION, DELAYED RELEASE;ORAL	021281-002	May 3, 2001		DISCN	No	No
Takeda Pharms Na	PREVACID IV	lansoprazole	INJECTABLE;INTRAVENOUS	021566-001	May 27, 2004		DISCN	Yes	No
Takeda Pharms Usa	PREVACID	lansoprazole	CAPSULE, DELAYED REL PELLETS;ORAL	020406-002	May 10, 1995	AB	RX	Yes	Yes
Takeda Pharms Na	PREVACID	lansoprazole	FOR SUSPENSION, DELAYED RELEASE;ORAL	021281-001	May 3, 2001		DISCN	No	No
Takeda Pharms Usa	PREVACID	lansoprazole	TABLET, ORALLY DISINTEGRATING, DELAYED RELEASE;ORAL	021428-002	Aug 30, 2002	AB	RX	Yes	Yes

International Patents for PREVACID

See the table below for patents covering PREVACID around the world.

Country	Patent Number	Title	Estimated Expiration
Hong Kong	4792	PYRIDINE DERIVATIVES AND THEIR PRODUCTION
Japan	S62277322	STABILIZED PHARMACEUTICAL COMPOSITION AND PRODUCTION THEREOF
Spain	2052697
Japan	2820319
Japan	3746167
Japan	H0244473
South Korea	100197465

Supplementary Protection Certificates for PREVACID

Patent Number	Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
1129088	2014/008	Ireland		PRODUCT NAME: DEXLANSOPRAZOLE OR A SALT THEREOF; NAT REGISTRATION NO/DATE: PA1864/001/001-002;PA1864/002/001-002 20131125; FIRST REGISTRATION NO/DATE: 47911 47912 47913 47914 20130919
0328535	96C0021	Belgium		PRODUCT NAME: LANSOPRAZOLE + CLARITHROMYCINE + METRONIDAZOLE; REGISTRATION NO/DATE IN FRANCE: K 27 17033R DU 19960209; REGISTRATION NO/DATE AT EEC: K 27 17033R DU 19960209
0174726	SPC/GB94/011	United Kingdom		SPC/GB94/011, EXPIRES: 20051210
0174726	93C0021	Belgium		PRODUCT NAME: LANSOPRAZOLE; NAT. REG.: 150 S 539 F 4 19921119; FIRST REG.: FR 333 412.1 19901211

Investment Scenario, Market Dynamics, and Financial Trajectory for PREVACID (Lansoprazole)

Last updated: February 3, 2026

Summary

PREVACID, a proton pump inhibitor (PPI) containing lansoprazole, has historically been a prominent treatment for conditions related to gastric acid hypersecretion. Key insights include:

• Market presence driven by indications such as GERD, NSAID-associated ulcers, and Zollinger-Ellison syndrome.
• Declining dominance due to patent expiry, generic competition, and the rise of alternative therapies.
• Potential for growth exists in biosimilars, OTC segments, and emerging markets.
• Overall, the financial trajectory suggests a transition from branded dominance to commoditized generics with evolving opportunities in niche and OTC markets.

---

1. Current Market Landscape for PREVACID

1.1 Market Position and Indications

PREVACID is approved for:

• Gastroesophageal reflux disease (GERD)
• Erosive esophagitis
• Zollinger-Ellison syndrome
• NSAID-associated gastric ulcers

Market Share (2022):

Segment	Share (%)	Notes
Branded PREVACID	<5	Declined post-generic entry
Generic Lansoprazole	60-70	Dominates now
OTC Lansoprazole	20-25	Significant growth in OTC segment
Others (PPIs)	5-15	Competition from omeprazole, esomeprazole

Source: IQVIA, 2022.

1.2 Competitive Landscape

Competitor	Market Share (%)	Key Differentiators
Omeprazole (Prilosec)	20	First-mover advantage, OTC availability
Esomeprazole (Nexium)	15	Higher potency, branded premium segment
Pantoprazole (Protonix)	10	Institutional use, favorable safety profile
Omeprazole + Sodium Bicarbonate	5	Over-the-counter combination products

Note: The global PPIs market is expected to grow at approximately 3.5%-4.0% CAGR through 2027 (Source: MarketsandMarkets).

---

2. Market Dynamics Affecting PREVACID

2.1 Patent Expiry and Generic Competition

• PREVACID's patent expired in the U.S. in 2010.
• Generic lansoprazole launched soon after, causing price erosion.
• Patent litigations and exclusivities in various jurisdictions delay new entrants but generally accelerate generic dominance.

2.2 Regulatory Policies and OTC Conversion

• The shift of lansoprazole from prescription to OTC (FDA approval in 2011 for OTC use) significantly increased accessible units.
• Policies favor generic and OTC availability to improve affordability and adherence.

2.3 Innovation and Biosimilars

• Unlike biologics, small-molecule PPIs like lansoprazole face limited biosimilar development.
• There's a limited pipeline for new formulations or indications that can sustainably revitalize PREVACID's market share.

2.4 Market Trends and Consumer Preferences

• Growing emphasis on lifestyle modifications for GERD.
• Preference for OTC PPIs over prescriptions in many markets.
• Rising awareness of gut health promoting OTC and preventative use.

---

3. Financial Trajectory and Investment Outlook

3.1 Revenue Decline Post-Patent Expiry

Year	Revenue (USD millions)	Key Events
2010	1,200	Patent expired; generic entry
2015	800	Market saturation; generic pricing pressure
2020	350	Shift to OTC sales; decreasing prescriptions
2022	200	Continued erosion

Source: Company annual reports, IQVIA.

3.2 Current Revenue Streams

Segment	Revenue Share (%)	CAGR (2017-2022)
Prescription (Rx)	30	-10% annually
OTC Lansoprazole	50	+5% annually
Generic Sales	20	Declining

3.3 Future Growth Opportunities

Opportunity	Potential CAGR	Strategic Drivers
OTC Market Expansion	3-4%	Increased self-medication, brand acquisition
Emerging Markets	5-7%	Growing healthcare infrastructure, affordability programs
Niche Indications (e.g., Helicobacter pylori eradication)	4-6%	New formulations, combination pills
Biosimilar/Advanced Delivery Systems	2-3%	Limited impact in small-molecule drugs

3.4 Key Risks

• Price erosion from generics.
• Regulatory hurdles in maintaining OTC status.
• Competition from novel therapies (e.g., potassium-competitive acid blockers like vonoprazan).
• Patent barriers for new formulations.

---

4. Comparative Analysis: PREVACID vs. Alternatives

Parameter	PREVACID (Lansoprazole)	Omeprazole (Prilosec)	Esomeprazole (Nexium)	Alternative Therapies
Patent Status	Expired	Expired	Expired
OTC Availability	Yes	Yes	Yes/No (varies)
Price Range (USD/tablet)	0.20 – 0.50	0.15 – 0.40	0.30 – 0.60
Indication Spectrum	Broad	Broad	Broad	Newer classes (potassium blockers)

Note: Market participants are increasingly favoring newer potassium-competitive acid blockers (e.g., vonoprazan), which may challenge PPI sales in future.

---

5. Investment Scenarios and Strategic Considerations

Scenario	Assumptions	Implication
Conservative	Continued generic-dominated erosion; OTC growth stabilizes	Revenue down to USD 150-200M in 2025; limited upside
Moderate	Entry of new formulations or combination products	Slight uptick in niche markets; stabilization of sales
Aggressive	Acquisition of OTC rights, or development of novel delivery systems	Potential for revenue revival in specific segments

Investment Recommendations

• Short-term: Caution due to market saturation; focus on OTC segment growth.
• Medium-term: Monitor pipeline of new formulations or combination therapies.
• Long-term: Consider positioning in emerging markets or niche indications with high unmet needs.

---

6. Regulatory and Policy Environment Impact

Policy Area	Impact on PREVACID	Notable Trends
Patent Law & Exclusivity	Accelerates patent expiries, generic entry	Patent litigations are critical for delay tactics
OTC Switch Regulations	Enhances OTC sales volume	Varies by country, US FDA allows OTC status for lansoprazole since 2011
Pricing & Reimbursement Policies	Pressure on prices, especially in public markets	Cost-effectiveness assessments influence market access

---

Conclusion

PREVACID's market outlook hinges on post-patent generic competition, OTC segment growth, and emerging market penetration. While the core product faces declining prescribed sales, strategic expansion into OTC and niche indications offers potential.

---

Key Takeaways

• Market maturation: The original prescription market has significantly declined post-patent expiry.
• Erosion of branded sales: Branded PREVACID sales are minimal relative to generic and OTC.
• Growth in OTC: OTC lansoprazole remains a key growth driver, especially in developed markets.
• Emerging markets: Growing healthcare infrastructure and affordability pose opportunities.
• Future innovation limits: The small-molecule landscape offers limited innovative pathways; alternative therapies (e.g., novel acid blockers) may overshadow PPIs.

---

FAQs

Q1: How has patent expiration impacted PREVACID's revenue?
A1: Patent expiry in 2010 led to immediate generic competition, causing a significant revenue decline; the drug transitioned into a largely OTC and generic market.

Q2: What are the main drivers for PREVACID's future growth?
A2: OTC availability, expansion into emerging markets, and potential development of combination therapies or new formulations.

Q3: How does PREVACID compare to competitors like Prilosec or Nexium?
A3: While initially competitively positioned, PREVACID's market share has diminished due to similar or superior efficacy, marketing, and brand recognition with competitors.

Q4: Are biosimilars or generics threatening PREVACID?
A4: Generics dominate, and biosimilars are not applicable to small-molecule drugs like lansoprazole, but further patent expirations could increase competition.

Q5: What regulatory challenges could impact future sales?
A5: Maintaining OTC status, negotiating reimbursement policies, and navigating patent protection for new formulations remain key regulatory considerations.

---

References

[1] IQVIA, 2022. US Prescription Market Data
[2] MarketsandMarkets, 2022. Proton Pump Inhibitors Market
[3] FDA, 2011. Lansoprazole OTC approval
[4] Company Annual Reports (2010-2022)
[5] GlobalData, 2022. Emerging Markets Pharmaceutical Trends